4. Nano Drug-delivery
• Nanomedicine uses nanoscale technologies (≤100 nm) for the
diagnosis, treatment and/or prevention of diseases
• It includes sustained delivery of
Therapeutic Agents,
Targeted Delivery Of Drugs
Reduced Side Effects
8. Gold Nanoparticles
• Plasmonic Vesicles of Amphiphilic Gold Nanocrystals: Self-Assembly
and External-Stimuli-Triggered Destruction
• Plasmonic vesicular nanostructures assembled from amphiphilic
gold nanocrystals with mixed polymer brush coatings.
• Analogous to block copolymers,the disruption of the plasmonic
vesicles can be triggered by stimulus mechanisms
• The development of multifunctional vesicles containing stimuli-
responsive polymers applications in theragnostic nanomedicine
10. Thermal ablation of cancer cells by
‘Silica-gold’ nano shells
• Thermal ablation of cancer cells by nanoshells coated with metallic layer and
by applying an external energy source to kill them
• Gold nps absorb light in the near infra red region becomes hot and can kill
the cells in their proximity
11.
12. Liposomes
• Liposomes are small spherical vesicles, composed of lipid bilayers surrounding
aqueous inner phase.
• Reservoir (i.e) Bilayers - hydrophobic drugs and inner aqueous phase - hydrophilic
drugs
• Liposomes -ocular drug delivery
• Encapsulation of idoxuridine into liposomes increased the corneal penetration of
the drug
• Variety of biomaterials for ocular drug delivery including
polymeric nanoparticles
dendrimers
hydrogels
13.
14.
15.
16. Lipid Nanoparticle Drug Delivery System
• Major problem with IV administration of colloidal particles is interaction with
reticulo-endothelial system (RES)
• Any foreign material, biological response to administered nanoparticle, coated by
proteins called opsonins, enhance uptake of coated material by RES
• Opsonins on particle surface creates a “molecular signature” recognized by
immune cells
• Lipid nanoparticles engineered to evade RES cells by limiting particle sizes to 200
nm or less.
• It is believed that these cells do not recognise low nanometer-sized particles as
foreign.
17.
18. Drug Delivery To BBB
• The BBB is single layer of endothelial cells in inner surfaces of capillaries
in the brain
• The endothelial cells fit tightly together and substances cannot pass out of
the bloodstream
• The mechanism for transport is endocytosis
• Endothelial cells with lipoprotein receptor transports the lipoprotein with
nanoparticle from the blood plasma.
19.
20.
21. Polymeric Nanoparticles On Drug Delivery
• Polymeric nps from natural and synthetic polymers have stability and ease
of surface modification
• Polymeric materials-biocompatible and biodegradable
• The polysaccharides polymeric materials to prepare nps for drug delivery.
• Biodegradable nanoparticles
nanocapsule
nanosphere
• The drug molecules are either entrapped inside or adsorbed on the surface.
22.
23. Chitosan Carrier In Nano Drug Delivery
System
• Chitosan (CS) is abundant naturally occurring polysaccharide
• Chitosan is made of randomly distributed β-(1-4)-linked D-glucosamine (deacetylated unit)
and N-acetyl-D-glucosamine (acetylated unit)
• It is produced by deacetylation of chitin extracted from shells of crabs, shrimps and krill.
• Chitosan attracted as
Matrix for controlled release due to its reactive functionalities
Easily degradation by enzymes
Non-toxic degradation products
• Hydrophobic interactions enhance stability of substituted CS by reducing hydration of matrix
,resisting degradation by gastric enzymes
26. TREATING CANCER WITH NANOPARTICLES
• Cancer therapeutics,chemotherapy serious side effects –
Devastation of healthy tissue
Some cancerous tissue survives after radiation
• Nanoparticles -targeted drug delivery systems
• Nps with UV-sensitive proteins,assemble with drug and cancer cell-
targeting protein fragment when exposed to UV.
• Nanoparticle-drug complex that specifically attaches to cancerous cells.
27.
28. Reference
• [1] Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000) Tumor vascular permeability
and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release 65, 271-84.
• [2] Palmer, T. N., Caride, V. J., Caldecourt, M. A., Twickler, J., and Abdullah, V. (1984) The
mechanism of liposome accumulation in infarction. Biochim. Biophys. Acta 797, 363-8.
• [3] Jaracz, S., Chen, J., Kuznetsova, L. V., and Ojima, I. (2005) Recent advances I tumortargeting
anticancer drug conjugates. Bioorg. Med. Chem. 13, 5043-54.
• [4] Torchilin, V. P. (2004) Targeted polymeric micelles for delivery of poorly soluble drugs. Cell
Mol. Life Sci. 61, 2549-59.
• [5] Gabizon, A., Shmeeda, H., Horowitz, A. T., and Zalipsky, S. (2004) Tumor cell targeting of
liposome-entrapped drugs with phospholipid- anchored folic acid-PEG conjugates. AdV. Drug
DeliVery ReV.56, 1177-92.